New Positive Dengue Vaccine Results From Sanofi’s Biggest Trial Yet

Sanofi today announced the positive results of a 20,000 strong phase III trial of their pioneering dengue vaccine This final study from Sanofi Pasteur, Sanofi’s vaccine arm, has demonstrated a 60.8 reduction in cases of dengue ¬†fever amongst it’s 20,875 strong population of 9-16 year olds in Latin America. This was accompanied by a 80% reduction in hospitalisations caused by …

Sanofi Pasteur’s Dengue vaccine Candidate Successfully Completes Final Landmark Phase III Clinical Efficacy Study in Latin America

Second, large-scale phase III study successfully meets primary endpoint with overall vaccine efficacy of 60.8 percent and shows efficacy against each of the four dengue serotypes – Additional observation of the results shows a significant reduction of the risk of hospitalization by 80.3 percent confirming the potential public health impact of the vaccine Initial safety data are consistent with the …